What is an NPI and why does this case revolve around it?

A National Provider Identifier is a unique number that identifies a licensed clinician across the U.S. healthcare system. Pharmacies and insurance systems use it to verify that a prescription was ordered by a real, accountable provider. The complaint alleges that Zealthy submitted prescriptions under the NPIs of clinicians who had not evaluated the patients in question, and in some instances had not been working for Zealthy at the time. Misuse of an NPI is what makes the allegation a fraud and prescribing-integrity issue rather than a marketing-only one.

Are GLP-1 medications dispensed through telehealth still safe?

The case does not say anything about the safety of GLP-1 medications themselves. The allegations are about how a specific company is alleged to have run its business, not findings about any particular medication. The medication you receive from a licensed pharmacy under a real clinician's prescription is governed by separate safety and quality rules, and the lawsuit does not change those.

Should I cancel my Zealthy subscription?

We do not give individual advice on whether to stay or leave a particular provider. What we can say is that any subscription is yours to manage, and reviewing your billing, your prescription source, and your continuity of care with a clinician you trust is reasonable in any moment of uncertainty about a provider.

What does this mean for telehealth more broadly?

It means federal regulators are paying close attention to the back end of telehealth, including who is actually prescribing and how subscriptions are billed and canceled. Most telehealth providers run real practices with state-licensed clinicians and accredited pharmacies. The questions worth asking of any provider, named in this case or not, are who your clinician is, where your medication is made, what the full price is before you give a card, and how you cancel if you need to.

What the Zealthy Lawsuit Means for Telehealth

Q: Is Zealthy shut down?

Not as of the latest reporting. The Department of Justice has asked a federal court to freeze the company's assets and appoint a receiver to run the business while the case proceeds, but the court has not ruled on those requests. The filing notes the requested remedies could bankrupt Zealthy if granted.

On April 14, 2026, the U.S. Department of Justice filed a motion in federal court asking a judge to freeze the assets of the telehealth company Zealthy and put the business under a court-appointed receiver, citing newly disclosed evidence that the company allegedly used foreign call center contractors to order prescriptions in the names of doctors who were not the patients' actual prescribers (Modern Healthcare).

Who This Helps

You are probably reading this if you saw a headline about a telehealth company being sued, are using or have considered Zealthy or another telehealth service for weight loss or another condition, or just want to understand what is happening in the industry and how to think about it as a patient. The case touches on a lot of the questions readers ask us about how to tell a real, well-run telehealth practice from one that is cutting corners.

This article walks through what the government is alleging, what is and is not yet proven, and what the broader picture means for anyone using telehealth today. The point is to give you the information so you can make your own decisions, not to tell you what to do.

Does This Affect My GLP-1 Medication?

If you do not use Zealthy, the case does not change anything about your prescription. Your medication, your pharmacy, and your provider relationship are not part of the proceedings.

If you do use Zealthy, the case is worth paying attention to because Zealthy is one of the larger telehealth providers selling compounded GLP-1 products for weight loss alongside other categories (TechTarget). The legal action is about how Zealthy is alleged to have run its business, not a finding that compounded GLP-1 medications themselves are unsafe, and not a finding against the licensed pharmacies that fill prescriptions. If a court grants the asset freeze and receivership the government is asking for, the operation of the business could change, and patients in active treatment may want to talk with a clinician they trust about continuity of care. We have a guide on how to evaluate telehealth and compounded GLP-1 providers if that is where your head is.

What the Government Is Alleging

The case originated in June 2024, when the Department of Justice filed suit against three telehealth companies on behalf of the Federal Trade Commission in the U.S. District Court for the Southern District of Florida (Sherwood News). The most recent motion, filed in April 2026, asks the court to take immediate action against Zealthy specifically based on documents the government says were uncovered during discovery (InsideHealthPolicy). The named individual defendant is Kyle Robertson, Zealthy's founder and CEO, who previously founded the mental health telehealth company Cerebral and was removed from that company in 2022 (Fierce Healthcare).

The government's central allegation is that Zealthy used foreign call center workers, including contractors based in the Philippines, to order thousands of prescriptions, and that those orders were submitted under the names and National Provider Identifier numbers of clinicians who had not actually evaluated the patients (Behavioral Health Business). One example cited in the filing involves a former Zealthy medical director, Dr. Steven McDonald, whose name and credentials were allegedly used to order more than 8,000 prescriptions after he had stopped working at the company, a pattern he discovered only when a colleague mentioned that his old office was receiving stacks of insurance letters for patients he had never treated (Modern Healthcare). A National Provider Identifier is the unique number that follows a clinician through their career and lets pharmacies and insurers verify that a real, licensed person ordered a prescription. Misusing one is a serious allegation because the system relies on those numbers to keep prescribing inside a circle of accountable clinicians.

The complaint also alleges that Zealthy ran consumer-facing marketing that told patients they could "Pay $0 today" and "Cancel anytime," while in practice charging tens of thousands of consumers without consent and using a multi-step cancellation flow that the filing describes as designed to add friction (Fierce Healthcare). Other allegations include directing the posting of fake online reviews and using patient health information to power social media ad campaigns without patient knowledge (Behavioral Health Business).

The relief the government is asking for is unusual. Beyond civil penalties, it wants the court to freeze the company's assets and appoint an outside receiver to run the business while the case proceeds, with a partner from the firm Alvarez & Marsal proposed as the receiver (Behavioral Health Business). The filing itself acknowledges the requested remedies could bankrupt the company (Sherwood News).

What This Is and Is Not

The complaint is a set of allegations, not a final ruling. The court has not yet decided whether to grant the asset freeze or the receivership, and Zealthy has not been found legally responsible for any of the conduct described. As of the most recent reporting, neither the company nor Kyle Robertson has publicly responded to media requests for comment (Behavioral Health Business). Cerebral, his former company, has noted publicly that Robertson has not been with that organization since 2022 and declined to comment on the current charges against him (Modern Healthcare).

The case is also about how a telehealth business is alleged to have operated, not a finding that any specific GLP-1 medication or other prescription was unsafe to take. Patient-safety claims and business-conduct claims are different categories. The complaint focuses on the second.

This is also one company. Patterns in a single case do not say anything definitive about the larger telehealth industry. There are many licensed, well-run telehealth practices that match patients with state-licensed clinicians, work with accredited pharmacies, and run transparent billing. Most of the questions readers should be asking apply to any provider, not just the one in the news.

What This Says About the Industry

Two things from the filing are worth understanding because they apply more broadly.

The first is the use of NPIs as the trust signal in remote prescribing. Pharmacies and insurance systems use the NPI to confirm that a real, licensed clinician ordered the prescription. Most patients do not see the NPI on the back end of their telehealth experience, and there is no easy way for a patient to verify whether the clinician on file with the pharmacy is the one who actually evaluated them. The case is one example of why federal regulators have been paying more attention to the back end of telehealth, even when the front end of the website looks polished.

The second is the gap between marketing copy and operational practice. The complaint's "Pay $0 today" and "Cancel anytime" language is the kind of phrasing patients see on telehealth landing pages every day. The line between aggressive but legal marketing and conduct that crosses into a consumer-protection violation is being actively tested in cases like this one. Patients reading those phrases on a homepage have no way to know which side of that line a particular company sits on. That is part of why federal enforcement is shifting toward making companies prove that the experience matches the promise.

The Cerebral history adds context. Cerebral, which Kyle Robertson founded before Zealthy, paid a $5.1 million settlement to the FTC in 2024 over health-information marketing and cancellation issues, and a $3.6 million fine to the Department of Justice that same year as part of a separate non-prosecution agreement (Fierce Healthcare). Two consecutive companies under the same founder facing federal enforcement is unusual, and it is part of why the current case is drawing the attention it is.

How to Evaluate Any Telehealth Provider

The case offers a useful lens on questions worth asking of any telehealth service, not just the one in the news.

You should be able to find out the name of the clinician who will actually be reviewing your case, and that name should match a real, state-licensed person you can look up in the relevant medical or nursing board database (Federation of State Medical Boards). Stock medical photos on a marketing page are common across the industry and are not by themselves a flag, because the actual clinician is often matched after sign-up. The accountability sits with the clinician who signs the prescription, not the model in the homepage hero shot.

Pricing should be visible before you enter card details. Final totals can move based on intake or labs, so a single number on the homepage is not realistic, but the monthly cost, shipping fees, consultation fees, and any lab charges should appear on a page you can reach without having handed over a payment method. "We will tell you at checkout" after card entry is a different experience than full disclosure before.

Cancellation should be roughly as easy as sign-up. If subscribing took two clicks and canceling requires a phone call, an email back-and-forth, or a multi-week notice period, that is information about how the business is run.

Media coverage claims should be verifiable. If a homepage shows logos from major outlets, the company should be able to point you to the specific articles or video clips. A wall of logos with no underlying links is a different signal than a press section with active citations.

The GLP Winner provider survey helps you compare telehealth options that publish clinician names, pharmacy details, and pricing up front. The insights hub also has plain-language guides on related topics if you want to read further before making a decision.

Final Takeaway

The Zealthy case is a complaint, not a verdict. The court has not yet ruled on whether to freeze the company's assets or whether the conduct described actually happened. As patients and readers, the most useful thing to do is take the questions the filing raises and apply them to any telehealth provider you are considering, including the one you may already use.

The questions are simple enough to ask out loud. Who is my clinician, and can I look them up. Where will my prescription be filled. What is the total cost before I hand over a card. How do I cancel if this stops working for me. Telehealth has made a lot of care more accessible, and most providers are running real practices. Knowing how to evaluate the ones that are not is part of being an informed patient in 2026.

If you enjoy posts like these, you can subscribe to receive newsletter updates.

What the Zealthy Lawsuit Means for Telehealth Patients

Who This Helps

Does This Affect My GLP-1 Medication?

What the Government Is Alleging

What This Is and Is Not

What This Says About the Industry

How to Evaluate Any Telehealth Provider

Final Takeaway

Sources

Keep Reading

How to Evaluate Telehealth & Compounded GLP-1 Providers: Your Search Guide

GLP-1 Access in 2026: What Telehealth Platforms Are Doing Differently Than a Year Ago

How to Find a GLP-1 Provider Online

Categories

Curated by